A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway

Figure 8

(a) Detection of apoptosis in MCF-7 cells by flow cytometry after treatment with the ruthenium-fluvastatin complex. (b) Detection of apoptosis in MDA-MB-231 cells by flow cytometry after treatment with the ruthenium-fluvastatin complex. (c) Percentage of apoptotic cells versus concentration in MCF-7 cells. (d) Percentage of apoptotic cells in the early and late apoptosis stage in MCF-7 cells. (e) Percentage of apoptotic cells versus concentration in MDA-MB-231 cells. (f) Percentage of apoptotic cells in the early and late apoptosis stage in MDA-MB-231 cells.

(a)

(b)

(c)

(d)

(e)

(f)